


Pilot study

45 serous cancers selected
for primary treatment
response



Validation study

100 serous cancers randomly
selected from a population-based
cohort

Supplementary Figure 1. Summary of all cases included in the pilot and validation sets. Following the recommendations of the REMARK guidelines we have reported the outcome of analysis of all cases in the study and have then focused on those that fulfilled the criteria of high grade (grade 2-3) late stage (FIGO stage III-IV) serous invasive ovarian cancers.